Zustand der körperlichen Auszehrung – Symptome und Behandlungsmethoden

The term **"cachexia"** originates from Latin (*cachexia*) and Ancient Greek, where *kakos* signified "harmful" or "poor," and *hexis* referred to "physical state" or "condition." Clinically, this syndrome is defined as **progressive, systemic wasting of the body**, most prominently characterized by **rapid and severe weight loss**—typically exceeding 5% of baseline body weight within a mere three-month period [1]. Alternative designations such as **"cancer-associated wasting"** or **"neoplastic cachexia"** are also employed in medical discourse to emphasize its **multifactorial metabolic dysfunction**, intrinsically linked to malignant diseases. Beyond adipose tissue depletion, the condition involves **accelerated skeletal muscle degradation**, profoundly impairing patients’ functional capacity and quality of life. When left untreated, cachexia triggers a **cascade of pathophysiological responses** that exacerbate clinical decline: a loss of over 30% of baseline weight renders continuation of anticancer treatment unfeasible and is frequently fatal—**estimates suggest that 20–40% of patients in advanced cancer stages succumb directly to cachexia-related depletion rather than the primary malignancy itself** [2]. The prevalence of this syndrome varies by cancer type: it affects **approximately 60% of individuals with colorectal, prostate, or lung cancers**, whereas its incidence **exceeds 80% in pancreatic and gastric malignancies**. A compounding challenge is the **co-occurring cancer anorexia** (loss of appetite), which hinders nutritional intervention efficacy and deepens the energy deficit.

The primary etiologic factor in the development of cachexia within malignant neoplasia is the progressive dysregulation of metabolic pathways, driven by excessive secretion of pro-inflammatory mediators—most notably tumor necrosis factor-alpha (TNF-α)—which exacerbates skeletal muscle proteolysis and sustains systemic inflammation. This metabolic derangement manifests as heightened energy expenditure, accelerated degradation of lean muscle mass, and uncontrolled catabolism of macronutrients, including proteins, lipids, and carbohydrates. Concurrently, neoplastic cells synthesize and release systemic proteolytic and lipolytic factors (such as interleukins IL-1 and IL-6), which directly induce weight loss, primarily through the depletion of fat-free muscle tissue. The resultant hormonal and metabolic imbalances lead to hypoproteinemia (reduced serum albumin and total protein levels), leukopenia, and anemia, culminating in a distinctive symptom complex characterized by chronic fatigue, physical debilitation, apathy, and progressive anorexia—a persistent loss of appetite that may evolve into food aversion. Patients frequently experience gastrointestinal disturbances, including intractable nausea, vomiting, diarrhea, and impaired gut motility, further exacerbating nutritional deficiencies. Mechanical obstruction caused by localized tumor growth (e.g., within the gastrointestinal tract) may additionally impede oral intake, nutrient absorption, and normal bowel function, thereby accelerating the organism’s progressive emaciation.

A constellation of clinical signs that patients, their family members, or caregivers frequently report: persistent and progressive weight decline (irrespective of baseline body mass), driven by the depletion of both adipose and muscle tissue; marked anorexia, premature satiety following consumption of minimal food quantities; profound physical debilitation, chronic fatigue, and diminished endurance; observable deterioration in skin condition (pallor, xerosis, sallow complexion), alterations in hair texture (dullness, fragility), peripheral edema (particularly in the hands and feet), cardiac arrhythmias, abdominal and hepatic discomfort; heightened susceptibility to infections (increased frequency and prolonged duration of illnesses), compromised immune function; escalating depressive symptomatology, social withdrawal, anxiety disorders, and generalized apprehension.

The principal therapeutic objective in cachexia management is the rapid restoration of optimal nutritional status through the implementation of a high-calorie, high-protein specialized diet supplemented with targeted nutritional interventions and pharmacological adjustments. A multidimensional approach encompasses control of the underlying disease (particularly malignancy), alleviation of dyspeptic symptoms such as nausea and vomiting, appetite stimulation, enhancement of digestive and absorptive processes, correction of anemia, and psychological support. The dietary regimen should feature elevated levels of high-quality protein to counteract accelerated protein catabolism, alongside a balanced fatty acid profile, vitamins, and micronutrients. Critical importance is placed on personalized meal planning that accommodates individual preferences and tolerances, emphasizing frequent, small-volume meals with high energy density—including liquid nutritional supplements. Evidence-based supplementation may include omega-3 fatty acids, vitamins D3 and K2, probiotics, curcumin, and antioxidant compounds. Moderate-intensity physical activity, such as walking, can facilitate appetite improvement, while a positive mealtime environment in the company of loved ones encourages increased food intake. Cachexia, recognized as cancer-associated wasting syndrome, affects up to 80% of patients in advanced-stage malignancy and is characterized by weight loss, muscle atrophy, fatigue, anemia, and metabolic/hormonal disturbances. Effective nutritional intervention can significantly enhance prognosis, quality of life, and the feasibility of continuing oncological treatment.